Trial Profile
Endocrine effects of Toremifene(Fareston) and Leuprolide(Leuplin) therapy in premenopausal breast cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2018
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary) ; Toremifene (Primary)
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- 10 Oct 2018 Status changed from active, no longer recruiting to completed.
- 28 Jul 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan.
- 20 Dec 2011 New trial record